InspireMD Inc
F:II2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
InspireMD Inc
F:II2
|
IL |
|
N
|
Nintendo Co Ltd
XBER:NTO
|
JP |
|
C
|
Currys PLC
SWB:CWB
|
UK |
|
Nippon Building Fund Inc
TSE:8951
|
JP |
|
Osaka Gas Co Ltd
OTC:OSGSF
|
JP |
|
Flughafen Zuerich AG
OTC:UZAPF
|
CH |
|
H
|
Hain Celestial Group Inc
XBER:HF1
|
US |
|
Cooper-Standard Holdings Inc
NYSE:CPS
|
US |
|
E
|
E ON SE
BMV:EOANN
|
DE |
|
Yangtze Optical Fibre and Cable Joint Stock Ltd Co
SSE:601869
|
CN |
|
M
|
MAG Silver Corp
LSE:0V56
|
CA |
|
C
|
Capita PLC
XMUN:CTAA
|
UK |
|
Ekso Bionics Holdings Inc
NASDAQ:CHRN
|
US |
|
Green Dot Corp
LSE:0J0N
|
US |
|
N
|
NWS Holdings Ltd
F:NWS
|
HK |
|
K
|
Koninklijke DSM NV
XHAM:DSM2
|
NL |
|
Calbee Inc
TSE:2229
|
JP |
InspireMD Inc
InspireMD makes medical devices used in blood-vessel procedures, especially stents and embolic protection systems. Its main product family is built around a thin mesh that is designed to catch debris that can break loose during treatment and travel downstream, which helps doctors treat blocked arteries more safely. The company sells to hospitals and physicians that perform cardiovascular and neurovascular procedures. The business makes money by selling these disposable devices to healthcare providers, often through direct sales teams and distribution partners. Its customers choose InspireMD’s products when they need tools for treating narrowed or blocked arteries in places such as the heart, neck, or other vessels where protecting against debris matters. The company sits in a specialized corner of the medical device market where the value comes from making procedures safer and easier to perform. What makes InspireMD different is its focus on protection during stent placement, not just opening the artery itself. That puts it in a niche between standard stent makers and broader surgical device companies. Its business depends on adoption by interventional doctors and hospital systems that want devices built for complex vascular cases.
InspireMD makes medical devices used in blood-vessel procedures, especially stents and embolic protection systems. Its main product family is built around a thin mesh that is designed to catch debris that can break loose during treatment and travel downstream, which helps doctors treat blocked arteries more safely. The company sells to hospitals and physicians that perform cardiovascular and neurovascular procedures.
The business makes money by selling these disposable devices to healthcare providers, often through direct sales teams and distribution partners. Its customers choose InspireMD’s products when they need tools for treating narrowed or blocked arteries in places such as the heart, neck, or other vessels where protecting against debris matters. The company sits in a specialized corner of the medical device market where the value comes from making procedures safer and easier to perform.
What makes InspireMD different is its focus on protection during stent placement, not just opening the artery itself. That puts it in a niche between standard stent makers and broader surgical device companies. Its business depends on adoption by interventional doctors and hospital systems that want devices built for complex vascular cases.
Revenue growth: Q1 revenue rose to $3.4 million, up 122% year over year, driven by the U.S. launch of CGuard Prime and stronger international sales.
U.S. pause: Management paused U.S. commercialization of CGuard Prime after identifying delivery-system issues in the controlled launch; they said the stent itself is not the problem and called the action proactive.
Guidance withdrawn: InspireMD withdrew its full-year 2026 revenue guidance until it has more clarity on FDA timing and the path back to the U.S. market.
FDA path: The company expects FDA approval for the original CGuard delivery system in the third quarter of 2026 and said it is working on design changes for CGuard Prime, with a possible return in early 2027 or sooner.
TCAR still on track: Management said the TCAR strategy remains intact, including expected approval of CGuard Prime 80 in the second half of 2026 and the start of the C-GUARDIANS III study.
Costs and cash: Operating expenses rose to $14.7 million, and cash and marketable securities were $41.6 million at quarter-end. The company also flagged about $700,000 of returns reserves and about $650,000 of inventory/remediation costs in Q2.
Demand remains: Management repeatedly emphasized strong physician interest and international demand, and said the pause should not affect the overseas business, which continues to use the original delivery system.
